Almirall S A : Chairman, Carlos Gallardo, appointed as Interim CEO

Almirall's Chairman, Carlos Gallardo, appointed as Interim CEO 03 November 2022

• Gianfranco Nazzi to leave the CEO role to pursue new opportunities

Barcelona (Spain), November 03, 2022.- Gianfranco Nazzi, CEO, has stepped down effective November 2nd from his role as CEO at Almirall to pursue new professional opportunities. The Board has appointed Carlos Gallardo, Chairman of the Board of Directors, as acting CEO while the company identifies the best suitable candidate to succeed Gianfranco.

Carlos Gallardo, Chairman of the Board of Directors, commented:

"On behalf of the Board of Directors of Almirall and the broader leadership team, I would like to thank Gianfranco for his dedication and the contributions he has made as CEO of Almirall. He joined us at a crucial moment and achieved strong results, maximizing the value of our product launches, attracting key talent, and preparing Almirall for the next growth phase. We wish him every success for his future.

There are great things happening in the company right now: the sustained growth of Ilumetri, the strong uptake of the recently launched Klisyri and Wynzora, and the excellent clinical data on lebrikizumab, the regulatory dossier of which has now been accepted for filing by the EMA. We can be proud to have such a late-stage pipeline which, together with the talented people we have in the company, provide a great basis for continued growth.

I am delighted with the progress the whole Almirall team is making in transforming the company into a leader in the field of Medical Dermatology. Helping patients suffering from severe dermatological conditions will continue to be at the centre of everything we do".

The process to identify the CEO successor has already been set in motion.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79- year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit www.almirall.com